| Neurologist Connect

Early Alzheimer disease: clinical decision points from first concern to diagnostic confirmation

Q1.

A 70-year-old patient reports new forgetfulness noticed by family members over the past year. Brief cognitive screening shows mild impairment, but daily function remains largely intact.

Which step most appropriately advances the evaluation for possible early Alzheimer disease?

A. Reassure the patient and repeat screening in 2–3 years

B. Diagnose Alzheimer disease based on screening results

C. Perform comprehensive cognitive evaluation and assess for potential underlying neurodegenerative etiology, including Alzheimer pathology

D. Start symptomatic therapy without further evaluation

Scroll for Answer Details

Correct Answer: C

Screening tools alone are insufficient to diagnose Alzheimer disease. When early cognitive impairment is suspected, clinicians should proceed with formal cognitive evaluation and consider biomarker-supported diagnostic assessment to determine the underlying etiology. Distinguishing mild cognitive impairment from normal aging or other causes is a critical decision point in early Alzheimer disease care.

https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14333

Early Alzheimer disease: clinical decision points from first concern to diagnostic confirmation

Q2.

Blood-based biomarkers are increasingly discussed as tools in Alzheimer disease evaluation.

In current clinical workflows, how are these tests most appropriately used?

A. As standalone diagnostic confirmation

B. As triage tools to identify patients who may benefit from confirmatory testing

C. Only in advanced dementia

D. Only for research purposes

Scroll for Answer Details

Correct Answer: B

Emerging blood-based biomarkers—particularly phosphorylated tau assays—may help identify patients likely to have Alzheimer disease pathology and guide referral for confirmatory PET or CSF testing. However, these biomarkers are not yet widely accepted as standalone diagnostic tests in routine clinical practice and should be interpreted alongside clinical findings.

https://www.nature.com/articles/s41582-024-00989-1

Early Alzheimer disease: clinical decision points from first concern to diagnostic confirmation

Q3.

In patients with suspected early Alzheimer disease, when is biomarker testing most clinically appropriate?

A. When dementia is already severe

B. When cognitive impairment is present and the underlying cause remains uncertain

C. When cognitive screening is normal

D. Only after several years of symptom progression

Scroll for Answer Details

Correct Answer: B

Biomarker testing is most useful when clinical evaluation identifies cognitive impairment but the etiology remains uncertain. Evidence of amyloid or tau pathology can help support diagnostic confidence. Results should be interpreted within the broader clinical context, as uncertainty may still remain. Clinicians should also discuss the limitations and evolving nature of biomarker testing with patients when aligning expectations.

https://www.sciencedirect.com/science/article/pii/S0929664626000537

Early Alzheimer disease: clinical decision points from first concern to diagnostic confirmation

Q4.

Which clinical situation should prompt re-evaluation or additional diagnostic workup in a patient with suspected early Alzheimer disease?

A. Stable cognition over several years

B. Mild cognitive concerns with a clear non-neurologic explanation

C. Progressive cognitive decline after an initially inconclusive evaluation

D. Absence of functional impairment

Scroll for Answer Details

Correct Answer: C

When cognitive decline continues after an initially inconclusive evaluation, clinicians should consider additional diagnostic workup, which may include repeat cognitive testing, biomarker assessment, or specialist referral. Early Alzheimer disease may evolve gradually, making ongoing reassessment essential to reaching an accurate diagnosis.

https://www.nature.com/articles/s41582-024-00989-1

Early Alzheimer disease: clinical decision points from first concern to diagnostic confirmation

Q5.

Following confirmation of early Alzheimer disease pathology, which strategy best supports ongoing patient management and care coordination?

A. Establish regular follow-up to monitor cognition, function, and care needs

B. Discontinue cognitive monitoring once diagnosis is established

C. Refer only if severe symptoms develop

D. Limit follow-up to primary care visits

Scroll for Answer Details

Correct Answer: A

Early Alzheimer disease requires longitudinal monitoring, including assessment of cognitive and functional changes, management of comorbidities, and coordination with caregivers and multidisciplinary teams. Regular follow-up enables clinicians to adjust care plans and support patients and families as needs evolve.

https://www.nature.com/articles/s41582-024-00989-1

Early Alzheimer disease: clinical decision points from first concern to diagnostic confirmation

Q6.

Which of the following is a key purpose of using standardized cognitive assessment tools during early Alzheimer disease evaluation?

A. To confirm Alzheimer disease pathology

B. To objectively measure cognitive impairment and help distinguish normal aging from mild cognitive impairment

C. To replace biomarker testing

D. To determine treatment eligibility or clinical trial eligibility

Scroll for Answer Details

Correct Answer: B

Standardized cognitive assessment tools (e.g., MoCA, MMSE, neuropsychological testing) help clinicians objectively evaluate cognitive domains such as memory, executive function, and attention. These assessments support differentiation between normal age-related changes and mild cognitive impairment, a key step in determining whether further diagnostic evaluation is warranted.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01296-0/abstract

Early Alzheimer disease: clinical decision points from first concern to diagnostic confirmation

Sign In